News articles about Tyme Technologies (NASDAQ:TYME) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tyme Technologies earned a news impact score of 0.10 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.4640959432135 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

TYME has been the topic of a number of recent analyst reports. BidaskClub raised Tyme Technologies from a “strong sell” rating to a “sell” rating in a research note on Tuesday. HC Wainwright initiated coverage on Tyme Technologies in a research note on Friday, December 15th. They set a “buy” rating and a $8.00 price target on the stock. Evercore ISI initiated coverage on Tyme Technologies in a research note on Friday, November 17th. They set an “outperform” rating and a $7.00 price target on the stock. Canaccord Genuity initiated coverage on Tyme Technologies in a research note on Wednesday, January 3rd. They set a “buy” rating on the stock. Finally, Zacks Investment Research lowered Tyme Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. Tyme Technologies currently has an average rating of “Hold” and an average target price of $8.25.

Shares of Tyme Technologies (NASDAQ TYME) traded down $0.48 during trading on Friday, hitting $2.29. The company’s stock had a trading volume of 4,464,428 shares, compared to its average volume of 245,096. Tyme Technologies has a one year low of $2.14 and a one year high of $9.50. The stock has a market cap of $251.80, a price-to-earnings ratio of -13.47 and a beta of -0.05.

In other Tyme Technologies news, CEO Steve Hoffman sold 17,986 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $3.82, for a total transaction of $68,706.52. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders have sold 20,286 shares of company stock worth $77,294.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at

About Tyme Technologies

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with's FREE daily email newsletter.